The Asian Development Bank has allocated $20.3 million to assist its developing members to access CoViD-19 vaccines and establish systems for fair and efficient vaccine distribution.
You are here
Results for CoViD-19 vaccine
Wednesday 18 November 2020
Thursday 27 August 2020
Wellington, New Zealand
New Zealand is increasing its chances of securing access to a CoViD-19 vaccine when it becomes available, after announcing millions of dollars to support domestic and international vaccine efforts. Prime Minister Jacinda Ardern is also ensuring Pacific Island countries are supported.
Wednesday 26 August 2020
Tonga has provided an Expression of Interest to join COVAX to access CoViD-19 vaccines confirmed the Ministry of Health CEO, Dr Siale ‘Akau’ola. It will give early access to vaccinations for the most vulnerable people in member countries populations.
Tuesday 28 July 2020
New York, USA
While ample resources – and high hopes – are being invested in the race to develop a COVID-19 vaccine, policymakers and the public should be preparing for a scenario in which no silver bullet is possible. But even in that case, writes renowned infectious disease expert William A. Haseltine, there are strong grounds to believe that we can control the virus and its spread.
Wednesday 22 July 2020
The Pacific region, including Tonga, is requesting access to a vaccine currently being developed to fight COVID-19, said the Minister for Health Hon ‘Amelia Tu’ipulotu today. They are talking to the World Health Organisation and taking part in preliminary discussions with the COVID-19 Vaccine Global Access (COVAX) Facility and GAVI, the Vaccine Alliance. It is hoped that by the end of 2021 there will be enough vaccine to immunise 20% of the population, starting with front line workers.
Monday 20 July 2020
New York, USA
Even if one or more vaccines emerge that promise to make people less susceptible to COVID-19, the public-health problem will not be eliminated. But policymakers can avert some foreseeable problems by starting to address key questions about financing and distribution now. The toughest political question of all, though, is likely to concern access. Who should receive the initial doses of any vaccine? Who determines who is allowed into the queue and in what order? By Richard N. Haass